Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 13583
Country/Region: Mozambique
Year: 2015
Main Partner: Columbia University
Main Partner Program: Mailman School of Public Health
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $27,667,525 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $3,683,670
Care: TB/HIV (HVTB) $637,769
Care: Pediatric Care and Support (PDCS) $818,625
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $250,000
Testing: HIV Testing and Counseling (HVCT) $1,826,540
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $2,477,716
Treatment: Adult Treatment (HTXS) $15,782,483
Treatment: Pediatric Treatment (PDTX) $2,190,722
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 31,137
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 43,390
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 15,416
FN_THER Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2016 3,905
FN_THER Number of PLHIV who were nutritionally assessed and found to be clinically undernourished 2016 5,209
FPINT_SITE Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services 2016 72
FPINT_SITE Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment 2016 72
GEND_GBV Number of people receiving post-GBV care 2016 2,495
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 217,773
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 274,957
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 1,610
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 2,943
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 4,015
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 2,943
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 1,610
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 1,177
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 2,405
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 1,766
PMTCT_ARV Sum of New and Current disaggregates 2016 4,015
PMTCT_ARV Sum of New and Current disaggregates 2016 2,943
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 3,642
PMTCT_STAT By: Known positives at entry 2016 463
PMTCT_STAT By: Known positives at entry 2016 852
PMTCT_STAT By: Number of new positives identified 2016 1,147
PMTCT_STAT By: Number of new positives identified 2016 2,091
PMTCT_STAT Number of new ANC and L&D clients 2016 90,845
PMTCT_STAT Number of new ANC and L&D clients 2016 34,489
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 94,381
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 36,213
PMTCT_STAT Sum of Positives Status disaggregates 2016 1,610
PMTCT_STAT Sum of Positives Status disaggregates 2016 2,943
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2016 1,327
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 1,196
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 31,137
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 43,390
TX_CURR Age/Sex: <1 Female 2016 295
TX_CURR Age/Sex: <1 Female 2016 263
TX_CURR Age/Sex: <1 Male 2016 295
TX_CURR Age/Sex: <1 Male 2016 263
TX_CURR Age/Sex: 1-4 Female 2016 674
TX_CURR Age/Sex: 1-4 Female 2016 603
TX_CURR Age/Sex: 1-4 Male 2016 674
TX_CURR Age/Sex: 1-4 Male 2016 603
TX_CURR Age/Sex: 5-14 Female 2016 471
TX_CURR Age/Sex: 5-14 Female 2016 425
TX_CURR Age/Sex: 5-14 Male 2016 471
TX_CURR Age/Sex: 5-14 Male 2016 425
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 21,796
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 30,377
TX_CURR Sum of age/sex disaggregates 2016 2,582
TX_CURR Sum of Age/Sex disaggregations 2016 2,880
TX_NEW Aggregated Grouping by Age: <1 Male 2016 101
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2016 101
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2016 10,762
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2016 5,797
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 17,542
TX_NEW Pregnancy status 2016 1,766
TX_NEW Sum of Age/Sex disaggregates 2016 460
TX_NEW Sum of Aggregated Age/Sex disaggregates 2016 16,559
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 5,677
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 8,119
Cross Cutting Budget Categories and Known Amounts Total: $406,896
Motor Vehicles: Purchased $406,896